JERUSALEM, Sept. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in September.HC Wainwright 21st Annual Global Investment ConferenceDate: September 8-10, 2

TEL AVIV, Israel, Sept. 3, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it has successfully completed the dose-escalation part of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a u

BINGHAM FARMS, Mich., Sept. 3, 2019 /PRNewswire/ -- The Kahn Center for Cardiac Longevity led by

WARSAW, Ind., Sept. 3, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2019.

CARNEGIE, Pa., Sept. 3, 2019 /PRNewswire/ -- My Secret Spa, an aesthetic practice  in Carnegie, Pennsylvania, is now offering a multitude of service

DUBLIN, Sept. 3, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Merck's Noxafil® (posaconazole) delayed-release tablets, 100 mg. Endo's subsidiary, Endo Ventures Limited, recently entered into

SAN DIEGO, Sept. 3, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in the following scientific and investor conferences

NASHVILLE, Tenn., Sept. 3, 2019 /PRNewswire/ -- SmileDirectClub, Inc. ("SmileDirectClub"), the industry pioneer and first direct-to-consumer medtech platform for transforming smiles, today announced that it has launched the road show for its initial public offering of shares of its Class A common stock. SmileDirectClub is offering 58,537,000 shares of its Class A common

ROSEMONT, Ill., Sept. 3, 2019 /PRNewswire/ -- Most smokers know cigarettes can damage their lungs, but all too often, they have no idea that smoking is also bad for their blood vessels.

SAN DIEGO, Sept. 3, 2019 /PRNewswire/ -- Viriom Inc., a clinical stage antiviral company focused on HIV and viral hepatitis (San Diego, CA), is developing long-acting versions of its once daily NNRTI inhibitor, elsulfavirine (Elpida®).  Phase I studies are ongoing, and will now be supplemented by an NIH/